{"blog": [], "keywords": [{"value": "Alexion Pharmaceuticals Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Synageva BioPharma Corp", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Biotechnology and Bioengineering", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/07/business/dealbook/alexion-to-buy-synageva-biopharma-in-8-4-billion-deal.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbWide.jpg", "legacy": {"wide": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/05/07/business/07db-drug-web/07db-drug-web-articleLarge.jpg", "xlargeheight": "422", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 422}, {"url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "727", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The deal taps into the interest for so-called orphan drugs, where companies can charge hundreds of thousands of dollars a year to treat rare diseases.", "pub_date": "2015-05-07T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Alexion, Maker of a Rare-Disease Drug, Buys Another", "main": "Alexion\u00a0to Buy Synageva BioPharma in $8.4 Billion Deal"}, "print_page": "9", "snippet": "The deal taps into the interest for so-called orphan drugs, where companies can charge hundreds of thousands of dollars a year to treat rare diseases.", "_id": "554a2ed738f0d838fba7397c", "slideshow_credits": null, "abstract": "Alexion Pharmaceuticals says it will buy Synageva BioPharma for about $8.4 billion; firm specializes in rare diseases, with new drug launching in 2015."}